Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1IMpower-130 (all population), 20191IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 20181IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel 0.89 [0.68; 1.17]0.89 [0.68;1.17]atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel 0.89 [0.68; 1.17]atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better 0.76 [0.63; 0.92]0.76 [0.63;0.92]atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better 0.76 [0.63; 0.92]atezolizumab plus carboplatin plus paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel 1.12 [0.85; 1.46]1.12 [0.85;1.46]atezolizumab plus carboplatin plus paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel 1.12 [0.85; 1.46]atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 0.85 [0.71; 1.02]0.85 [0.71;1.02]atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 0.85 [0.71; 1.02]bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better 1.32 [1.08; 1.60]1.32 [1.08;1.60]bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus bevacizumab plus carboplatin plus paclitaxel atezolizumab plus bevacizumab plus carboplatin plus paclitaxel better 1.32 [1.08; 1.60]bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel 1.18 [0.98; 1.42]1.18 [0.98;1.42]bevacizumab plus carboplatin and paclitaxel vs. atezolizumab plus carboplatin plus paclitaxel 1.18 [0.98; 1.42]bevacizumab plus carboplatin and paclitaxelatezolizumab plus carboplatin plus nab-paclitaxelatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus carboplatin plus paclitaxeldirect evidencenetwork meta-analysis
T vs. C bevacizumab plus carboplatin and paclitaxelatezolizumab plus carboplatin plus nab-paclitaxelatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus carboplatin plus paclitaxel
bevacizumab plus carboplatin and paclitaxel---NA1.32
1.08; 1.60		1.18
0.98; 1.42
atezolizumab plus carboplatin plus nab-paclitaxelNA---NANA
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel0.76
0.63; 0.92		NA---0.89
0.68; 1.17
atezolizumab plus carboplatin plus paclitaxel0.85
0.71; 1.02		NA1.12
0.85; 1.46		---

pathologies: 165 - treatments: 744 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons